Brief: Pliant Therapeutics Q3 Net Income USD -26.301 Million
06/11/2025 21:05
Nov 06 (Reuters) - Pliant Therapeutics Q3 operating expenses USD -28.269 million. Q3 operating income USD -28.269 million
Recent news on Pliant Therapeutics
See all newsBrief: Pliant Therapeutics Announces Presentations At The 2026 Annual Meeting
Brief: Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals